A randomized clinical trial to evaluate the single ‐dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes

ConclusionsSingle doses of sitagliptin as high as 200  mg were generally well tolerated in 10‐ to 17‐year‐old male and female study participants with T2DM, and a daily sitagliptin dose of 100 mg is appropriate for evaluation in Phase III safety and efficacy studies in pediatric patients with T2DM. (ClinicalTrials.gov: NCT00730275).

Source: Pediatric Diabetes - November 13, 2018 Category: Endocrinology Authors: Iain P. Fraser, Naomi D. Neufeld, Larry A. Fox, Mark S. Kipnes, Tracie L. Miller, Philip S. Zeitler, Henry Rodriguez, Jocelyn H. Gilmartin, Susan J. Lee, Jaclyn K. Patterson, Xiujiang S. Li, Lata Maganti, Wen ‐Lin Luo, Daniel A. Tatosian, Tags: ORIGINAL ARTICLE Source Type: research